DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Application based on results from the TROPION-Breast01 Phase III trial
The validations confirm the completion of the applications and commence the scientific review process
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The money will be donated to the United Nations Children’s Fund (UNICEF)
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Subscribe To Our Newsletter & Stay Updated
